Oncology & Cancer

Sickle cells show potential to attack aggressive cancer tumors

By harnessing the very qualities that make sickle cell disease a lethal blood disorder, a research team led by Duke Medicine and Jenomic, a private cancer research company in Carmel, Calif., has developed a way to deploy ...

Oncology & Cancer

Two-drug combination may slow deadly thyroid cancer

A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs together ...

Oncology & Cancer

COUP-TFII sparks prostate cancer progression

Prostate cancer presents a dilemma for patients and the physicians who treat them. Which cancers are essentially indolent and present no risk and which are life threatening? Which can be watched and which need aggressive ...

Oncology & Cancer

Boosting immune responses against leukaemia

(Medical Xpress)—In the first of its kind, a translational study undertaken at the Malaghan Institute of Medical Research has revealed that boosting the activity of a rare type of immune cell could be an effective way to ...

Oncology & Cancer

Hedgehog pathway key in tamoxifen-resistant breast CA

(HealthDay)—Noncanonical Hedgehog (Hh) signaling is activated in tamoxifen-resistant tumors, and the phosphoinositide 3-kinase inhibitor/protein kinase B (PI3K/AKT) pathway plays a key role protecting Hh signaling molecules, ...

page 25 from 35